Recommendations for the clinical interpretation and reporting of copy number gains using gene panel NGS analysis in routine diagnostics by Eijkelenboom, A. (Anneke) et al.
ORIGINAL ARTICLE
Recommendations for the clinical interpretation and reporting
of copy number gains using gene panel NGS analysis in routine
diagnostics
Astrid Eijkelenboom1 & Bastiaan B. J. Tops2 & Anke van den Berg3 & Adrianus J. C. van den Brule4 &
Winand N. M. Dinjens5 & Hendrikus J. Dubbink5 & Arja ter Elst3 & Willemina R. R. Geurts-Giele5 &
Patricia J. T. A. Groenen1 & Floris H. Groenendijk5 & Daniëlle A. M. Heideman6 & Manon M. H. Huibers7 &
Cornelis J. J. Huijsmans4 & Judith W. M. Jeuken8 & Léon C. van Kempen3 & Esther Korpershoek5 & Leonie I. Kroeze1 &
Wendy W. J. de Leng7 & Carel J. M. van Noesel9 & Ernst-Jan M. Speel10 & Maartje J. Vogel11 & Tom van Wezel12 &
Petra M. Nederlof11 & Ed Schuuring3 & Marjolijn J. L. Ligtenberg1,13
Received: 4 December 2018 /Revised: 14 February 2019 /Accepted: 3 March 2019 /Published online: 19 March 2019
Abstract
Next-generation sequencing (NGS) panel analysis on DNA from formalin-fixed paraffin-embedded (FFPE) tissue is increasingly
used to also identify actionable copy number gains (gene amplifications) in addition to sequence variants. While guidelines for
the reporting of sequence variants are available, guidance with respect to reporting copy number gains from gene-panel NGS data
is limited. Here, we report on Dutch consensus recommendations obtained in the context of the national Predictive Analysis for
THerapy (PATH) project, which aims to optimize and harmonize routine diagnostics in molecular pathology. We briefly discuss
two common approaches to detect gene copy number gains fromNGS data, i.e., the relative coverage and B-allele frequencies. In
addition, we provide recommendations for reporting gene copy gains for clinical purposes. In addition to general QC metrics
associated with NGS in routine diagnostics, it is recommended to include clinically relevant quantitative parameters of copy
number gains in the clinical report, such as (i) relative coverage and estimated copy numbers in neoplastic cells, (ii) statistical
scores to show significance (e.g., z-scores), and (iii) the sensitivity of the assay and restrictions of NGS-based detection of copy
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number gains. Collectively, this information can guide clinical and analytical decisions such as the reliable detection of high-level
gene amplifications and the requirement for additional in situ assays in case of borderline results or limited sensitivity.
Keywords Copy number gain . Amplification . NGS . Targeted therapy . Routine diagnostics . Molecular pathology
DiagnosticNGS gene panels allow parallel detection of high-level
gene amplifications associated with targeted therapy. In the
Netherlands, eight molecular pathology laboratories currently
have included copy number analyses in their routine NGS
work-up and one laboratory is in the midst of the validation pro-
cedure (Supplementary Table 1) and [1–3]. Due to the lack of
standard procedures and guidelines, the method of determining,
interpreting, and reporting these potential clinically actionable
gains vary among the different laboratories (Supplementary
Table 1). Guidelines to report the clinically relevant sequence
variants in cancer (i.e., small indels and single-nucleotide variants)
are extensive [4, 5], but are scarce with respect to somatic copy
number gains [6]. The Predictive Analysis for THerapy (PATH)
project is a national initiative to optimize and harmonize the rou-
tine diagnostics in molecular pathology across the Netherlands. A
national meeting was arranged, resulting in recommendations for
the interpretation and reporting of copy number gains using gene
panelNGSdata and to support adequate interpretation and clinical
decision-making. Here we focus on high-level copy number
gains, also described as high-level gene amplifications, that can
entail therapeutically targetable aberrations (reviewed in [7]).
High-level copy number gains can be more reliably detected than
copy number losses or low-level copy number gains when apply-
ing gene (hot spot) panels of limited size.
Detection of copy number gains from gene
panel NGS data
With an increased number of genomic DNA (gDNA) template
molecules available for targeted sequencing, gene copy number
gains will be reflected by an increased abundance of these genomic
segments in the libraries and consequently result in an increased
number of sequencing reads covering the respective (part of a) gene.
To identify these coverage outliers in gene panel NGS data, several
approaches have been described [8–11]. For details onmethods and
software used in routine diagnostics in the Netherlands, see
Supplementary Table 1.Note that at thismoment Bbest practices^
are yet to be determined and the choice ofmethod and software is
generally based on in house availability and validation.
Generally, these approaches start with sample normalization to
correct for differences in total reads, which is especially required in
the context of formalin-fixed paraffin-embedded (FFPE) tissue
analyses with variable input quality and quantity of gDNA. It is
of importance that the applied normalizationmethod is not affected
by the presence of high-level copy number gains. For example, the
median coverage is more stable relative to average or summed
coverage in the presence of high-level copy number gains. In
addition, the genomic locations covered by the gene panel should
be sufficiently spread throughout the genome covering multiple
loci, to allow appropriate normalization in the presence of a high-
level amplified gene. Subsequently, the obtained normalized read
count per amplicon and/or per gene can be compared to a reference
pool of (control) samples to estimate the copy number. From this
comparison, statistical measures such as relative coverage (also
often referred to as Bfold change^) and z-scores can be deduced
(Fig. 1). The choice for an internal or external reference pool (that
is, reference samples are analyzed within the same or a different
batch) and the minimal size of this reference pool depends on
diagnostic batch size, batch content, and the stability of the assay
and should therefore be determined during validation. One should
keep in mind that aneuploidy in tumors can affect normalization
and the quantification might be an underestimation or overestima-
tion depending on the nature and extend of aneuploidy and the
number of genomic regions that are included in the gene panel.
Therefore, the gene panel should also include genes/loci that are
not expected to be affected byCNVin themalignancies of interest.
The z-score is a significance score commonly used in the de-
tection of copy number variation from coverage data. This score
represents the number of standard deviations that the obtained
coverage is above or below the mean of a reference group of
values. Therefore, it greatly depends on testing conditions, includ-
ing the number of data points for a given locus and the analytical
noise that causes variations in control samples or between dupli-
cate analyses of the same sample. In a similar manner, the confi-
dence interval is a statistical measure representing the variation in
a reference group of samples and reflects whether the measure-
ment likely lies within the reference group interval. Consequently,
while z-scores and other measures like confidence intervals are
essential to distinguish analytical noise from actual copy number
variation and thus reflect the statistical significance of a copy
number variation, they are also greatly influenced by the standard
deviation that depends on laboratory- and test-specific conditions
Fig. 1 Detection of copy number gains from gene panel NGS coverage
data. a The absolute coverage per amplicon from theoretical gene panel
NGS data for three samples is shown, in which Gene B is amplified in
sample 2. Multiple data points (i.e., amplicons) are presented per gene. b
In this example, the normalized coverage per amplicon is obtained by
correction with the median coverage of all amplicons within that sample.
c The normalized coverage allows a comparison with the average
normalized coverage of multiple samples in an internal or external
reference pool. d, e Relative coverage (also referred to as Bfold-change^)
and z-scores (depicted above the bars) can be presented per amplicon (d) and
per gene (e). fThe influence on technical variations is illustrated by results in
which the same relative coverage is obtained, with 2-fold increased standard
deviations mimicking inter-laboratory technical differences
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(see also Fig. 1e, f). In the following paragraphs, the z-score is
used as a representative for any significance score that can be used
to distinguish noise from actual copy number gains.
By applying validated thresholds, significant coverage gains
can be identified that reflect gene amplifications. Note that the
relative coverage of individual amplicons within an amplified
gene can differ. Generally, poorly performing amplicons with a
low absolute coverage in control samples tend to obtain a lower
relative coverage in case of high-level amplifications, likely due
to technical saturation. The required total number of amplicons
per gene depends on the technical variability and should be de-
termined during validation. Distribution of amplicons throughout
the gene locus is preferred to prevent false positive calls from
partial gene amplifications, while keeping in mind frequently
deleted regions like the exons 2 to 7 in EGFRvIII [12].
A second commonly used approach to detect copy number
variation using NGS data is based on variant allele frequencies
of germline (single-nucleotide) polymorphisms (SNPs) at the
gene loci. These so-called B allele frequencies (BAFs) were
initially described for SNP-based array analysis [13]. For het-
erozygous SNPs, the variant allele frequency in gDNA from
normal tissue approaches 50%. In the presence of copy num-
ber gains, the variant allele frequency is increased when the B/
minor allele is amplified and likewise decreased with amplifi-
cation of the A/major allele (Fig. 2).
The relative coverage and BAF approaches are comple-
mentary. For example, the BAF approach requires coverage
information to discriminate copy number gains from copy
number losses. With sufficient BSNP-density^ the BAF ap-
proach can be more sensitive to detect low copy number ab-
errations (such as gene deletions or duplications), while the
relative coverage approach is more reliable in the quantitative
assessment of higher-level copy number gains (Fig. 3).
Regardless of the applied method, it is recommended to use
positive and negative control samples in which the copy num-
ber gains are confirmed by alternative approaches such as fluo-
rescence in situ hybridization (FISH), SNP-array analysis, or
multiplex ligation-dependent probe amplification (MLPA).
After validation, positive and negative control samples should
also be analyzed on a regular basis, to ensure stability of the
assay. Analytical cutoff values should be established that trans-
late into reliable and significant copy number gains, preferably
for all individual genes of interest. Since analysis of gDNA of
limited input quantity and/or quality may result in suboptimal
coverage and subsequently lead to false positive calls, the use of
minimal coverage thresholds is also recommended.
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Fig. 2 Detection of copy number variation using B-allele frequencies
(BAF). a In case of heterozygosity, variant allele frequencies (or BAFs)
are influenced by copy number variation at the respective loci. Here, for a
hypothetical case with a neoplastic cell load of 50% the NGS-based BAF
(y axis) is shown for an increasing number of alleles (x axis). b An
example of BAFs of common SNPs at the gene loci of the NGS results
of sample 2, presented in Fig. 1, in which Gene B is amplified. Every
circle represents the variant allele frequency of a common SNP. Dark gray
circles represent homozygous alleles. Blue circles represent heterozygous
alleles for which the BAF is within the expected ~50% (40–60% range).
Yellow circles represent heterozygous alleles for which the BAF is diver-
gent from this range due to amplification of the reference allele (decreased
BAF) or amplification of the variant allele (increased BAF)
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Clinically relevant measures of gene
amplification
Currently, the clinical relevance of gene amplifications is
largely based on molecular analyses by in situ approaches
such as FISH. The presence of gene copy number gains in
single neoplastic nuclei has been correlated with clinical re-
sponses towards drugs targeting the product of the amplified
gene. However, the above-described, NGS-based measure-
ments are obtained from the total gDNA template molecules
in the sample and as such represent a mixture of tumor-derived
and non-neoplastic gDNA from stromal and inflammatory
cells. The measured gain is thus determined by both the neo-
plastic cell percentage and the actual allele copy number
(Fig. 4a). To relate the NGS detected gains to FISH detected
gains, the calculated number of alleles could be corrected for
the estimated percentage of neoplastic nuclei in the area from
which the gDNAwas isolated.While we realize the estimation
of this percentage is error-prone [14, 15], it can be supported
by the variant allele frequencies (VAF) of somatic vari-
ants in other genes and it allows estimation of the num-
ber of gene copies in the Border of magnitude^ required
to asses clinical relevance. As mentioned above, the
estimation of the actual copy number gains may be bi-
ased in highly aneuploid tumors. For clinical decision
making, high copy number gains are most relevant for
which the estimation of allele copy number will be less
affected compared to low copy number alterations.
It is important to assess the clinical relevance of an estimat-
ed copy number on a case-by-case basis. For example, for the
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Fig. 3 Changes in BAF and relative coverage are affected by the allele
copy number. The effect of the number of alleles present in the neoplastic
cells on BAF (blue) or relative coverage (green) in case of a neoplastic
cell load of 50%. Generally, the BAF values are more divergent with
lower number gains like duplications and the resolution decreases with
higher-level copy number gains, while relative coverage increases
linearly (until technical saturation is reached)
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Fig. 4 The relative coverage is
affected by both neoplastic cell
load and the allele copy number
of the amplified gene. a The allele
copy number can be estimated
from relative coverage. Here, the
copy number (y axis) is calculated
with decreasing neoplastic cell
load (x axis) for a range of relative
coverages. For example, a relative
coverage of 10 in case of a
neoplastic cell load of 30%
represents an estimated copy
number of 62 alleles (see dashed
line). b The detection limit of the
assay can be estimated based on
neoplastic cell load. In this
example with a relative coverage
of 3.0 as a validated analytical
cutoff, the minimum detectable
allele copy number in the
neoplastic cells is shown with
decreasing neoplastic cell load
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tyrosine kinase inhibitor (TKI) crizotinib a FISH established
cutoff of 10 copies of the MET gene in lung adenocarcinoma
has been suggested [16], while only very limited data on the
response related to low-level (4–9 copies) and high-level (≥ 10
copies) amplification are presently available [17, 18]. For
capmatinib targetingMET in EGFRmutated lung adenocarci-
nomawith disease progression on EGFR-TKI treatment, gains
of ≥ 6 copies have been related to response to combinedMET
and EGFR targeting [19]. For example, in case an estimated
copy number gain of 30 copies of MET in the tumor cells is
detected by gene panel NGS analysis, TKI treatment could
directly be considered, while an estimated number more close-
ly to 6 copies warrants subsequent FISH analysis for clinical
guidance. Depending on the results of the internal validation, a
confirmatory FISH analysis can be performed in a subset of
cases. It is important to realize that these cutoffs differ per
therapeutic agent, gene, and tumor type. To determine the
optimal cutoff for treatment responses, several trials are ongo-
ing; e.g., FGFR1 amplification levels predicting clinical ben-
efit for inhibitors targeting FGFR1 appear drug and tumor
dependent [20].
Note that in FISH analyses typically only 50–100
selected nuclei are analyzed. While this enables specific
investigation of neopastlic nuclei, which is hampered by
admixture of non-neoplastic cells in NGS-based analy-
sis, it creates a potential bias that this selection is not
representative for the whole neoplastic area (for in-
stance, the selection can favor nuclei with multiple sig-
nals). For NGS-based approaches, the data represents an
average of a much larger number of cells (e.g., 20 ng
represents ~3300 nuclei). To ultimately evaluate the
clinical use of FISH- and NGS-based diagnostics, both
should be included in clinical trials focusing on treat-
ment response.
Table 1 Technical considerations for detection of copy number gains (gene amplifications) using panel NGS data
Technical issue Why relevant? Considerations
Panel content Panel size and selection of genomic loci
can affect detection of copy number
gains
(i) Contains amplicons/probes sufficiently spread throughout the genome
(ii) Includes loci likely to not be affected by copy number variation in tumor of interest
(iii) Minimal number of amplicons/probes per gene, preferably throughout gene locus
(iv) For BAF, include sufficient number of heterogeneous loci for sufficient BSNP-density^
Normalization Required to correct for differences in
gDNA input quality/quantity
Choose method that is not/minimally affected by copy number variation
Reference pool Is required to detect coverage outliers
indicative of copy number gains
(i) Internal and/or external reference pool
(ii) Includes samples without copy number variation (e.g., normal tissue)
(iii) Processed using identical protocols
Thresholds Required to distinguish genuine copy
number gains from technical noise
(i) Validated by positive/negative controls using other methods
(ii) Includes minimal coverage thresholds to prevent false positive calls from poor
quality gDNA
(iii) Include positive and negative controls on a regular basis, to ensure assay stability and
test validated thresholds
Sensitivity Awareness of assay limitations is
critical for routine diagnostics
(i) Affected by thresholds and neoplastic cell percentage
(ii) Should be included in clinical report
Table 2 Biological phenomena that affect the detection of copy number gains using panel NGS data
Biological phenomena Why relevant? How does it affect detection of copy number gains?
Neoplastic cell content Measurements are obtained
from a mixture of tumor-derived
and non-neoplastic gDNA
(i) The actual detected increase in coverage/deviation in BAF increases with neoplastic
cell content
(ii) Influences the estimation of the allele copy number
(iii) Determines assay sensitivity (in combination with thresholds used to identify
statistically significant gains)
Allele copy
number/magnitude
of amplification
Clinical consequences are based
on cutoffs in allele copy number
of gene amplification
(i) The detected increase in coverage/deviation in BAF increases with allele copy number
(ii) Assay sensitivity should match the clinically relevant cutoffs in alllele copy number
Aneuploidy Can affect normalization and
allele copy number estimation
(i) Results in underestimation or overestimation depending on the nature and
extend of aneuploidy and the number of genomic regions that are included in the
gene panel
(ii) High-level copy number gains are likely less affected compared to low copy
number alterations
678 Virchows Arch (2019) 474:673–680
Clinical reporting of NGS-based copy number
gain analysis
The clinical report that describes the results of the NGS-based
analysis of copy number gains should include the interpreta-
tion, e.g., Bamplification detected of gene X,^ Bno indications
for the presence of amplifications,^ Binconclusive,^ or Baddi-
tional testing required.^ In addition, it is essential to include
quantitative information as well as assay limitations.
Quantitative information includes the relative coverage that
reflects the total number of alleles present in the gDNA sam-
ple. Relative to BAFs, this measure provides a more linear
read-out of allele copy number. For loci with a significant
copy number change, based on the minimal validated relative
coverage and z-score or confidence interval, it is recommend-
ed to report the relative coverage and the estimated number of
copies in the neoplastic cells by taking the estimated neoplas-
tic cell percentage into account.
Awareness of assay limitations is critical for routine diagnos-
tics, as illustrated by the necessity to include the Breportable
range^ for NGS-based detection of sequence variants, like the
fraction of the targeted genomic regions for which calls of an
acceptable quality can be generated [5]. For the report of copy
number gain detection, it is essential to specify the estimated
sensitivity as the minimum amount of gene copies that can
reliably be measured as a copy number gain. Note that generally
these NGS-based analyses are not sufficiently sensitive to reli-
ably exclude the presence of any copy number gain in case of
low neoplastic cell percentages. Therefore, the threshold for
copy number gains also depends on the percentage of neoplastic
cells (Fig. 4b). We suggest a sentence such as BBased on the
estimated neoplastic cell percentage, this assay allows detection
of copy number gains of >XX copies.^ This sensitivity is also
crucial to decide on the necessity to perform additional analyses.
Conclusions
High-level copy number gains (gene amplifications) of clini-
cally targetable genes can be detected using NGS gene (hot
spot) panels in which multiple independent genomic regions
are included. Tables 1 and 2 summarize the technical consid-
erations and biological phenomena impacting on the detection
of these copy number gains. NGS gene panel-based analysis
has the advantage that high-level copy number gains in mul-
tiple genes can be measured simultaneously in addition to
sequence variant detection. As such, independent assays to
determine copy number gains may not be needed for a subset
of tumors, improving turn-around times, cost-efficiency, and
tissue management. A limitation of an NGS-based approach is
the difficulty to detect low-level copy number gains and/or
high-level amplifications in specimens with low neoplastic
cell percentages. For these cases, in situ analyses including
FISH are recommended to either exclude or confirm the pres-
ence of copy number gains. We recommend reporting relative
coverage and the estimated copy numbers in neoplastic cells
for loci that reach a minimal validated relative coverage and
significance score, as these parameters represent both quanti-
tative and clinically relevant measures. Clinical validity of the
identified copy number gain needs to be interpreted on a case-
by-case basis.
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